Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Plant-based vegetarian and vegan diets may have the lowest carbon footprint in the United States, but new data analysis shows fish-based pescatarian diets are the best.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Five new papers highlight cancer inequities, challenges and opportunities in South Asia
2.
Alkem introduces cetuximab under the trade name Cetuxa in India.
3.
Atezolizumab + Cabozantinib Postpones mCRPC Progression.
4.
Researchers have determined that malignancy hibernation will be the next front in the fight against breast cancer.
5.
More evidence links physical activity with improved cancer survival
1.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
2.
Thyroidectomy & Survival: Highlights from ASCO 2025 and Current U.S. Findings
3.
Uncovering the Reality of Colon Cancer: A Look at Real Images
4.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
5.
The Ultimate Guide to Understanding Abiraterone and its Uses in Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge